Bristol Myers Squibb (BMY)

[DewDiligence]

EXEL/IPN.PA/BMY—Opdivo/Cabometyx statsig superior PFS/OS to Sutent monotharpy in first-line RCC in CHECKMATE-9ER study:

https://finance.yahoo.com/news/bristol-myers-squibb-exelixis-announce-105900676.html

A tweet says that the HR for PFS was 0.51, and the HR for OS was 0.60 (

$EXEL
KN-426 at 12m
PFS: HR 0.69 (worse than 9ER)
OS: HR 0.53 (better than 9ER with short f/u)

KN-426 (at 16.6m f/u at KCA, Jan 2, 2019)
PFS: HR 0.69 (still worse than 9ER)
OS: HR 0.59 (same as 9ER)

EXEL 9ER at 18.1m f/u
PFS: HR 0.51
OS: HR 0.60

— AT (@BioSyncopation) April 20, 2020

), although these data are not in the above PR.

As I’m typing… EXEL +24%; IPN.PA +6%; BMY +2%.